In summary, we can conclude that all current transgenic mouse models of HER2-induced BC have advanced our understanding of how HER2 promotes tumor progression and leads to poor patient prognosis, identifying target genes that function downstream of, or in concert with, HER2. This evidence concerns the gene ERBB2 and neoplasm.